Pharmacogenetic Study of the Impact of <i>ABCB1</i> Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients
Psoriasis is a chronic, T cell-mediated skin disease affecting 2–3% of the Caucasian population. Cyclosporine A is a calcineurin inhibitor that acts selectively on T cells. The cyclosporine A treatment response has been suggested to be modulated by single-nucleotide polymorphisms (SNPs) in the <i...
Main Authors: | Alexandr Chernov, Daria Kilina, Tatiana Smirnova, Elvira Galimova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/11/2441 |
Similar Items
-
Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review
by: Sunil Dogra, et al.
Published: (2017-01-01) -
Cyclosporine
by: Nahide Onsun
Published: (2022-04-01) -
Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01) -
The Effect of Systemic Methotrexate and Cyclosporine Combination Therapy inPsoriasis Vulgaris Patients in Bandung, Indonesia
by: Oki Suwarsa, et al.
Published: (2021-11-01) -
Influence of <i>ABCB1</i> <i>3435C>T</i> polymorphism on methotrexate safety in patients with psoriasis
by: Alexey A. Kubanov, et al.
Published: (2023-02-01)